Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

The Brazilian standardization of the MATRICS consensus cognitive battery (MCCB): Psychometric study

2017; Elsevier BV; Volume: 185; Linguagem: Inglês

10.1016/j.schres.2017.01.006

1573-2509

Ana Olívia Fonseca, Arthur de Almeida Berberian, Carolina de Meneses-Gaya, Ary Gadelha, Marcella de O. Vicente, Keith H. Nuechterlein, Rodrigo A. Bressan, Acioly L.T. Lacerda,

Functional Brain Connectivity Studies

Translate, adapt, and validate the MATRICS Consensus Cognitive Battery (MCCB) in Brazil.The present study followed three steps: 1) translation to Portuguese, cultural adaptation, and back translation to English; 2) completion of a pilot study (N=30) conducted with the purpose of assessing whether the general comprehension of the items was clear and all participants adequately responded to the battery; 3) completion of a Reliability and Validation Study of the Brazilian version of the MCCB with 99 individuals with schizophrenia and 99 healthy subjects. All participants were administered the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) and patients were also rated on the Global Assessment of Functioning (GAF) Scale and the Positive and Negative Symptoms Scale (PANSS).The results showed adequate to high levels of baseline and 4-week retest reliability, except the MSCEIT-ME; adequate internal consistency for the MSCEIT-ME for the total sample and patients group, and moderate Alpha for the health control sample; as well as evidence of convergent validity and sensitivity to differentiate performance between the groups. All the 10 MCCB measures showed the lowest learning effects.Overall the Brazilian version of the MCCB showed similar results to the original North American version. Our findings provides reassurance that the MCCB is a reliable and valid measure of cognition across different countries and cultures, which is especially important to the ongoing work in attempting to discover cognition-enhancing drugs and the effects of cognitive interventions for the treatment of schizophrenia.